Is tailored systemic therapy in renal cell carcinoma realistic?

Abstract

The development of immune checkpoint inhibitors has substantially altered the treatment strategy for patients with metastatic renal cell carcinoma and has improved patient survival. 1 Ljungberg B Albiges L Bedke J et al. Guidelines on renal cell carcinoma. European Association of Urology, Arnhem, the Netherlands2022 Google Scholar Several regimens are available as first-line therapy. However, there are no guidelines for choosing the best regimen for each patient in the real-world setting because of the absence of optimal biomarkers. 1 Ljungberg B Albiges L Bedke J et al. Guidelines on renal cell carcinoma. European Association of Urology, Arnhem, the Netherlands2022 Google Scholar Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trialWe demonstrate the feasibility and positive effect of a prospective patient selection based on tumour molecular phenotype to choose the most efficacious treatment between nivolumab with or without ipilimumab and a VEGFR-TKI in the first-line treatment of metastatic clear-cell renal cell carcinoma. Full-Text PDF